ReShape Lifesciences Inc. Stock

Equities

RSLS

US76090R2004

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:30:00 2024-04-26 pm EDT 5-day change 1st Jan Change
0.1698 USD -4.61% Intraday chart for ReShape Lifesciences Inc. +2.72% -32.00%
Sales 2024 * 9.99M Sales 2025 * 11.99M Capitalization 3.98M
Net income 2024 * -6M Net income 2025 * -5M EV / Sales 2024 * 0.4 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.33 x
P/E ratio 2024 *
-0.38 x
P/E ratio 2025 *
-0.47 x
Employees 29
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.83%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.61%
1 week+2.72%
Current month-7.92%
1 month-6.70%
3 months-17.53%
6 months-23.55%
Current year-32.00%
More quotes
1 week
0.17
Extreme 0.1651
0.18
1 month
0.16
Extreme 0.158
0.21
Current year
0.14
Extreme 0.1414
0.30
1 year
0.14
Extreme 0.1414
2.80
3 years
0.14
Extreme 0.1414
475.00
5 years
0.14
Extreme 0.1414
738.00
10 years
0.14
Extreme 0.1414
1 000 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 20-01-31
Director of Finance/CFO 63 21-06-14
Compliance Officer - -
Members of the board TitleAgeSince
Director/Board Member 66 15-12-31
Chairman 70 15-10-31
Director/Board Member 70 21-06-14
More insiders
Date Price Change Volume
24-04-26 0.1698 -4.61% 318,579
24-04-25 0.178 +5.89% 176,187
24-04-24 0.1681 -1.41% 117,465
24-04-23 0.1705 +2.16% 180,674
24-04-22 0.1669 +0.97% 103,794

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT

More quotes
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.1698 USD
Average target price
1 USD
Spread / Average Target
+488.93%
Consensus